This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Summary
Rilmenidine is an I1-imidazoline receptor agonist used to treat hypertension.
- Generic Name
- Rilmenidine
- DrugBank Accession Number
- DB11738
- Background
Rilmenidine has been used in trials studying the treatment of Hypertension and Chronic Kidney Disease.
- Type
- Small Molecule
- Groups
- Approved, Investigational
- Structure
Structure for Rilmenidine (DB11738)
- Weight
- Average: 180.251
Monoisotopic: 180.126263143 - Chemical Formula
- C10H16N2O
- Synonyms
- HYPERIUM
- Rilmenidine
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
- Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug eventsImprove clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events & improve clinical decision support.- Pharmacodynamics
Not Available
- Mechanism of action
Target Actions Organism UAlpha-2A adrenergic receptor Not Available Humans - Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAcebutolol The therapeutic efficacy of Rilmenidine can be decreased when used in combination with Acebutolol. Aceclofenac The therapeutic efficacy of Rilmenidine can be decreased when used in combination with Aceclofenac. Acemetacin The therapeutic efficacy of Rilmenidine can be decreased when used in combination with Acemetacin. Acetylsalicylic acid Acetylsalicylic acid may decrease the antihypertensive activities of Rilmenidine. Aclidinium The risk or severity of Tachycardia can be increased when Aclidinium is combined with Rilmenidine. Adenosine The risk or severity of Tachycardia can be increased when Adenosine is combined with Rilmenidine. Alclofenac The therapeutic efficacy of Rilmenidine can be decreased when used in combination with Alclofenac. Aldesleukin Aldesleukin may increase the hypotensive activities of Rilmenidine. Alfentanil Alfentanil may decrease the antihypertensive activities of Rilmenidine. Alfuzosin Alfuzosin may increase the hypotensive activities of Rilmenidine. 
Identify potential medication risksEasily compare up to 40 drugs with our drug interaction checker.Get severity rating, description, and management advice.Learn more - Food Interactions
- Avoid alcohol. Concomitant use is not recommended as alcohol may increase the sedative effects of rilmenidine.
- Take with food. However, the bioavailability of rilmenidine is not affected by food.
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Product Ingredients
Ingredient UNII CAS InChI Key Rilmenidine Phosphate 59QD64Q32M 85409-38-7 ZJCOWRFWZOAVFY-UHFFFAOYSA-N
Categories
- ATC Codes
- C02AC06 — Rilmenidine
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as oxazolines. These are organic compounds containing 1,3-oxazoline, a five-membered ring with a nitrogen and an oxygen atoms at the 1- and 3-position, respectively. Additionally, it contains two double bonds.
- Kingdom
- Organic compounds
- Super Class
- Organoheterocyclic compounds
- Class
- Azolines
- Sub Class
- Oxazolines
- Direct Parent
- Oxazolines
- Alternative Parents
- Isoureas / Propargyl-type 1,3-dipolar organic compounds / Oxacyclic compounds / Carboximidamides / Azacyclic compounds / Organopnictogen compounds / Organooxygen compounds / Hydrocarbon derivatives
- Substituents
- Aliphatic heteromonocyclic compound / Azacycle / Carboximidamide / Hydrocarbon derivative / Isourea / Organic 1,3-dipolar compound / Organic nitrogen compound / Organic oxygen compound / Organonitrogen compound / Organooxygen compound
- Molecular Framework
- Aliphatic heteromonocyclic compounds
- External Descriptors
- isourea (CHEBI:8862)
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- P67IM25ID8
- CAS number
- 54187-04-1
- InChI Key
- CQXADFVORZEARL-UHFFFAOYSA-N
- InChI
- InChI=1S/C10H16N2O/c1-2-7(1)9(8-3-4-8)12-10-11-5-6-13-10/h7-9H,1-6H2,(H,11,12)
- IUPAC Name
- N-(dicyclopropylmethyl)-4,5-dihydro-1,3-oxazol-2-amine
- SMILES
- C1CC1C(NC1=NCCO1)C1CC1
References
- General References
- TITCK Product Information: Hyperium (rilmenidine) oral tablets [Link]
- External Links
- KEGG Compound
- C11120
- PubChem Compound
- 68712
- PubChem Substance
- 347828096
- ChemSpider
- 61963
- BindingDB
- 50070328
- 55679
- ChEBI
- 8862
- ChEMBL
- CHEMBL289480
- ZINC
- ZINC000000009708
- Wikipedia
- Rilmenidine
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 4 Withdrawn Treatment Chronic Kidney Disease (CKD) / High Blood Pressure (Hypertension) 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Tablet Tablet, coated Oral 1 mg - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 1.34 mg/mL ALOGPS logP 1.43 ALOGPS logP 1.58 ChemAxon logS -2.1 ALOGPS pKa (Strongest Basic) 7.11 ChemAxon Physiological Charge 1 ChemAxon Hydrogen Acceptor Count 3 ChemAxon Hydrogen Donor Count 1 ChemAxon Polar Surface Area 33.62 Å2 ChemAxon Rotatable Bond Count 3 ChemAxon Refractivity 49.79 m3·mol-1 ChemAxon Polarizability 20.38 Å3 ChemAxon Number of Rings 3 ChemAxon Bioavailability 1 ChemAxon Rule of Five Yes ChemAxon Ghose Filter Yes ChemAxon Veber's Rule Yes ChemAxon MDDR-like Rule No ChemAxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available
Targets
Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock newinsights and accelerate drug research.
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- General Function
- Thioesterase binding
- Specific Function
- Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is oxymetazo...
- Gene Name
- ADRA2A
- Uniprot ID
- P08913
- Uniprot Name
- Alpha-2A adrenergic receptor
- Molecular Weight
- 48956.275 Da
References
- Zhu QM, Lesnick JD, Jasper JR, MacLennan SJ, Dillon MP, Eglen RM, Blue DR Jr: Cardiovascular effects of rilmenidine, moxonidine and clonidine in conscious wild-type and D79N alpha2A-adrenoceptor transgenic mice. Br J Pharmacol. 1999 Mar;126(6):1522-30. [Article]
Drug created at October 20, 2016 20:43 / Updated at May 27, 2021 02:57